222 related articles for article (PubMed ID: 37120640)
21. Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model.
Brave SR; Eberlein C; Shibuya M; Wedge SR; Barry ST
Angiogenesis; 2010 Dec; 13(4):337-47. PubMed ID: 20953695
[TBL] [Abstract][Full Text] [Related]
22. The vascular endothelial growth factors and receptors family: Up to now the only target for anti-angiogenesis therapy.
Tarallo V; De Falco S
Int J Biochem Cell Biol; 2015 Jul; 64():185-9. PubMed ID: 25936669
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic paradigm of dual targeting VEGF and PDGF for effectively treating FGF-2 off-target tumors.
Hosaka K; Yang Y; Seki T; Du Q; Jing X; He X; Wu J; Zhang Y; Morikawa H; Nakamura M; Scherzer M; Sun X; Xu Y; Cheng T; Li X; Liu X; Li Q; Liu Y; Hong A; Chen Y; Cao Y
Nat Commun; 2020 Jul; 11(1):3704. PubMed ID: 32709869
[TBL] [Abstract][Full Text] [Related]
24. The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF.
Ghalehbandi S; Yuzugulen J; Pranjol MZI; Pourgholami MH
Eur J Pharmacol; 2023 Jun; 949():175586. PubMed ID: 36906141
[TBL] [Abstract][Full Text] [Related]
25. Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects.
Li D; Xie K; Zhang L; Yao X; Li H; Xu Q; Wang X; Jiang J; Fang J
Cancer Lett; 2016 Jul; 377(2):164-73. PubMed ID: 27130666
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
Haspel HC; Scicli GM; McMahon G; Scicli AG
Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
[TBL] [Abstract][Full Text] [Related]
27. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
[TBL] [Abstract][Full Text] [Related]
28. Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy.
Elebiyo TC; Rotimi D; Evbuomwan IO; Maimako RF; Iyobhebhe M; Ojo OA; Oluba OM; Adeyemi OS
Cancer Treat Res Commun; 2022; 32():100620. PubMed ID: 35964475
[TBL] [Abstract][Full Text] [Related]
29. Angiogenesis inhibitors: a rational strategy for radiosensitization in the treatment of non-small-cell lung cancer?
Raben D; Helfrich B
Clin Lung Cancer; 2004 Jul; 6(1):48-57. PubMed ID: 15310417
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment.
Liu G; Chen T; Ding Z; Wang Y; Wei Y; Wei X
Cell Prolif; 2021 Apr; 54(4):e13009. PubMed ID: 33655556
[TBL] [Abstract][Full Text] [Related]
31. Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer.
Riondino S; Del Monte G; Fratangeli F; Guadagni F; Roselli M; Ferroni P
Cardiovasc Hematol Agents Med Chem; 2017; 15(1):3-16. PubMed ID: 28137223
[TBL] [Abstract][Full Text] [Related]
32. Novel multi-targeted inhibitors suppress ocular neovascularization by regulating unique gene sets.
Yin X; Lin X; Ren X; Yu B; Liu L; Ye Z; Chen Q; Lee C; Lu W; Yu D; Li X
Pharmacol Res; 2019 Aug; 146():104277. PubMed ID: 31112749
[TBL] [Abstract][Full Text] [Related]
33. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
[TBL] [Abstract][Full Text] [Related]
34. [VEGF and its receptors as therapeutic target in cancer therapy].
Gisterek I; Kornafel J
Przegl Lek; 2006; 63(3):155-7. PubMed ID: 16967703
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor.
Zhu Z; Witte L
Invest New Drugs; 1999; 17(3):195-212. PubMed ID: 10665474
[TBL] [Abstract][Full Text] [Related]
36. gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor.
Basaki Y; Chikahisa L; Aoyagi K; Miyadera K; Yonekura K; Hashimoto A; Okabe S; Wierzba K; Yamada Y
Angiogenesis; 2001; 4(3):163-73. PubMed ID: 11911014
[TBL] [Abstract][Full Text] [Related]
37. LHT7, a chemically modified heparin, inhibits multiple stages of angiogenesis by blocking VEGF, FGF2 and PDGF-B signaling pathways.
Chung SW; Bae SM; Lee M; Al-Hilal TA; Lee CK; Kim JK; Kim IS; Kim SY; Byun Y
Biomaterials; 2015 Jan; 37():271-8. PubMed ID: 25453957
[TBL] [Abstract][Full Text] [Related]
38. Sequential delivery of VEGF, FGF-2 and PDGF from the polymeric system enhance HUVECs angiogenesis in vitro and CAM angiogenesis.
Bai Y; Bai L; Zhou J; Chen H; Zhang L
Cell Immunol; 2018 Jan; 323():19-32. PubMed ID: 29111157
[TBL] [Abstract][Full Text] [Related]
39. Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects.
Sledge GW
Semin Oncol; 2002 Jun; 29(3 Suppl 11):104-10. PubMed ID: 12138404
[TBL] [Abstract][Full Text] [Related]
40. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.
Fernando NT; Koch M; Rothrock C; Gollogly LK; D'Amore PA; Ryeom S; Yoon SS
Clin Cancer Res; 2008 Mar; 14(5):1529-39. PubMed ID: 18316578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
